Aureka Biotechnologies announced the completion of a US$100 million Series B financing round on August 10, 2026. Granite Asia provided the first tranche as the sole investor, while a leading …
Nona Biosciences (“Nona”), a biotechnology company focused on advancing biologics discovery and development through proprietary technology platforms, has announced a strategic partnership with Lonza to create advanced single-domain antibody-based blood-brain …
At the 17th Annual Meeting of the New Champions (Summer Davos 2026), organized by the World Economic Forum in Dalian on June 23, Gong Yingying, Founder and Chairwoman of Yidu …
Intensity Therapeutics, Inc., a late-stage biotechnology firm, focuses on discovering and developing proprietary cancer treatments using its non-covalent drug-conjugation technology. This approach is designed to destroy tumors while enhancing the …
Marking more than 15 years of partnership with Europe’s drug discovery community, Viva Biotech is reinforcing its dedication to the region through operational consistency, steady growth, and scalable collaboration. As …
Hyundai Bioscience has revealed an ambitious new plan aimed at addressing worldwide viral outbreaks, confirming the launch of its Phase 2 clinical trials in the United States. During its presentation …
Innovation forms the cornerstone of our endeavors within the pharmaceutical sector. Our objectives are straightforward: to pioneer novel medicines addressing crucial unmet medical needs, and subsequently, establish the requisite infrastructure …
Cadence Molecular Sciences, a division of Cadence Design Systems, is set to supply molecular design tools from OpenEye to energize the open-science, AI-powered Structure-enabled Antiviral Platform (ASAP) Discovery Consortium. This …
